How to Help Your Patients Save Money on D.H.E. 45: A Provider's Guide to Savings Programs

For many patients with chronic migraine or cluster headache, D.H.E. 45 (dihydroergotamine mesylate) is one of the most effective medications available. It is also one that carries significant out-of-pocket cost burdens — particularly for brand formulations, those without insurance, or those on high-deductible plans. As a provider, you have real leverage to help patients access this medication affordably. This guide covers every cost-reduction strategy available in 2026.

Understanding the Cost Landscape

D.H.E. 45 pricing varies significantly by formulation:

Generic dihydroergotamine mesylate injectable (1 mg/mL ampules) — Retail cash price: $335–$733 for 5–10 mL ampules. With GoodRx coupon: as low as $262. With insurance: typically Tier 2–3, moderate copay.

Generic DHE nasal spray (Migranal, 8 vials) — Retail cash price often exceeds $3,000; with GoodRx: approximately $262–$270.

Brand products (Trudhesa, Brekiya) — Brand pricing without assistance can be very high. Manufacturer savings programs are essential to reduce patient cost.

In addition to cost, availability remains a concern — the generic injectable is in active shortage as of 2026. Prescribing decisions must account for both cost and availability.

Strategy 1: Prescribe Generic When Clinically Appropriate

The generic dihydroergotamine mesylate injectable is FDA-approved and bioequivalent to the original D.H.E. 45 brand. When clinically appropriate — and when the injectable can be sourced during the current shortage — it is the most cost-effective option. Write prescriptions generically ("dihydroergotamine mesylate injection, 1 mg/mL") to allow pharmacies to substitute generics.

For patients who cannot use the injectable (due to difficulty with self-injection or unavailability), generic DHE nasal spray (Migranal generic) is available with discount coupons, often at prices comparable to the injectable.

Strategy 2: Advise Patients on GoodRx and Discount Cards

Prescription discount cards can dramatically reduce out-of-pocket cost, especially when cash price beats the insurance copay or when the patient is uninsured. For dihydroergotamine mesylate:

GoodRx — Prices starting at approximately $262. Free to use. Accepted at CVS, Walgreens, Walmart, Kroger, and thousands of independent pharmacies.

GoodRx Gold — Paid membership (~$9.99/month); can reduce price further (as low as ~$283 per fill in some data).

SingleCare, RxSaver, WellRx, BuzzRx — Free alternative discount card services; prices may vary by pharmacy.

Remind patients that GoodRx cannot be used simultaneously with Medicare Part D — they must choose one or the other per fill.

Strategy 3: Manufacturer Savings Programs for Brand DHE Products

If you're prescribing Trudhesa or Brekiya — due to shortage of the generic injectable, clinical preference, or patient-specific need — manufacturer programs can make these brand products more affordable:

Trudhesa Savings Program (Impel Pharmaceuticals) — Commercially insured patients may be eligible for copay assistance, potentially reducing out-of-pocket cost to $0/month. Contact Impel or the specialty pharmacy for enrollment. Uninsured patients may qualify for patient assistance programs.

Brekiya Patient Support (Amneal Pharmaceuticals) — Amneal may offer copay support for commercially insured patients. Ask the specialty pharmacy managing Brekiya dispensing for current program details.

Note: Manufacturer copay cards are generally not applicable for Medicare, Medicaid, or other federally funded insurance programs.

38,224+ patients found their medications in stock

38K+

Find D.H.E. 45 In Stock Today →

Strategy 4: Optimize Prior Authorization Submissions

When patients need brand DHE products (Trudhesa, Brekiya) due to shortage of or failure with the generic injectable, insurance coverage depends on a successful PA. Reduce approval time and increase success rate by:

Documenting the active ASHP shortage of generic dihydroergotamine mesylate injection (listed since August 2024).

Documenting patient-specific steps already taken to locate the generic (pharmacies checked, stock unavailable).

Framing the request as a shortage exception rather than brand preference.

Including clinical rationale for DHE specifically (e.g., triptan failure, cardiovascular contraindications to triptans).

Strategy 5: Help Medicare Patients Navigate Their Coverage

For Medicare patients, specific strategies help:

The Medicare Part D $2,000 annual out-of-pocket cap (effective 2025) provides protection from catastrophic medication costs. Patients who reach the cap pay $0 for covered medications for the rest of the year.

Low-income Medicare patients may qualify for Extra Help/LIS (Low Income Subsidy), which significantly reduces or eliminates copays. Encourage eligible patients to apply through Social Security.

If DHE is early in a patient's year (before deductible met), sometimes GoodRx may be cheaper. Compare both at the time of fill.

Skip the calls, skip the stress.

Find D.H.E. 45 In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Strategy 6: Uninsured or Underinsured Patients — PAP Programs

Uninsured or underinsured patients who cannot afford DHE even with coupons should be directed to:

NeedyMeds.org — Database of pharmaceutical manufacturer assistance programs. Search "dihydroergotamine" for available programs.

RxAssist.org — Another comprehensive resource for finding manufacturer PAP programs.

HRSA-funded community health centers — Offer sliding-scale care and 340B pricing on medications for qualifying patients.

Strategy 7: Integrate Pharmacy Access Support Into Your Practice

During an active shortage, medication cost is only part of the problem — patients also can't find it. Recommending a pharmacy search service like medfinder for providers solves both problems simultaneously: medfinder calls pharmacies near the patient to find who has D.H.E. 45 in stock, saves the patient hours of calling around, and surfaces the pharmacies where they can also compare prices. For practices that see significant DHE patient volumes, recommending medfinder reduces office call volume and improves patient outcomes.

For a patient-facing version of this content, share our article on how to save money on D.H.E. 45 in 2026 with your patients.